文献速递肝病消化道肿瘤与早癌消化道出血

基因编辑猪肝辅助性异种移植首例活体人受者171天生存报告

Genetically engineered pig-to-human liver xenotransplantation.
PubMed 文献 · J Hepatol · 2025-10-09

全球首例10基因编辑猪肝辅助性异种移植给活体人受者,术后前31天无超急性或急性排斥、感染及重大并发症,肝肾功能稳定;术后38天因异种移植相关血栓性微血管病(xTMA)移除辅助肝,经依库珠单抗和血浆置换缓解,但反复上消化道出血致患者于术后171天死亡。该研究提示辅助性猪肝异种移植可作为桥接人肝移植的可行方案,而xTMA是长期成功的重大挑战。

要点

  • 10基因编辑猪肝辅助性异种移植活体人首例,术后前31天无排斥感染,肝肾功能稳定。
  • 术后38天因xTMA移除辅助肝,依库珠单抗联合血浆置换成功缓解xTMA。
  • 患者最终因反复上消化道出血于术后171天死亡,xTMA是长期成功的关键挑战。

核心结论

  • 辅助性猪肝异种移植作为桥接人肝移植可行,但术后xTMA是长期成功的重大挑战,需进一步研究改善结局。

研究设计与样本

  • 将10基因编辑猪肝作为辅助器官移植给右肝大肝癌且初始不适合根治性切除的患者,围术期密切监测肝功能、代谢和凝血指标。

主要发现

  • 术后前31天无超急性或急性排斥、感染或重大并发症,肝肾功能稳定。
  • 术后早期凝血病表现为D-二聚体和纤维蛋白降解产物升高,经抗凝治疗成功管理。
  • 术后38天因xTMA移除辅助肝,依库珠单抗和血浆置换成功缓解xTMA。
  • 患者因反复上消化道出血于术后171天死亡。

关键数值与推荐

  • 供肝含10个靶向基因编辑,包括敲除异种抗原基因和敲入7个人源转基因以改善免疫和凝血兼容性。
  • 术后前31天无超急性或急性排斥、感染或重大并发症。
  • 术后38天移除辅助肝,xTMA经依库珠单抗和血浆置换缓解。
  • 患者术后171天死亡。

临床怎么用

  • 辅助性猪肝异种移植可作为桥接人肝移植的可行方案,围术期需密切监测凝血和血栓性微血管病。
  • 术后xTMA可尝试依库珠单抗联合血浆置换管理,上消化道出血需积极防治。

局限性

  • 单例活体人受者报告,结果外推需谨慎。
  • 原文未报告长期免疫抑制方案细节及xTMA具体诊断标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The advent of genetically edited pig-to-human xenotransplantation has predominantly focused on cardiac and renal applications, with no reported cases of pig-to-human liver xenotransplantation. This study presents the world's first successful genetically modified pig auxiliary liver xenotransplantation in a living human, achieving unprecedented survival of 171 days, and provides valuable insights into the critical factors influencing the procedure's success. METHODS: A genetically modified pig liver, incorporating 10 targeted gene edits, was transplanted as an auxiliary organ into a patient with large hepatocellular carcinoma in the right hepatic lobe, which was initially deemed ineligible for curative resection. Liver function, metabolic, and coagulation markers were closely monitored throughout the perioperative period. RESULTS: For the first 31 days post-transplant, no hyperacute or acute rejection, infections, or significant complications were observed, and the patient's hepatic and renal function remained stable. Early postoperative coagulopathy, as indicated by elevated D-dimer and fibrin degradation products, was successfully managed through anticoagulant therapy. However, on postoperative day 38, the auxiliary liver was removed due to xenotransplantation-associated thrombotic microangiopathy (xTMA). Subsequent management with eculizumab and plasma exchange successfully resolved the xTMA. Unfortunately, repeated upper gastrointestinal hemorrhage ultimately led to the patient's death on day 171. CONCLUSIONS: This study demonstrates the feasibility of auxiliary porcine liver xenotransplantation as a bridging approach to human liver transplantation. Postoperative xTMA presents a significant challenge to long-term success, highlighting the need for further research to improve xenotransplantation outcomes. IMPACT AND IMPLICATIONS: This study reports the world's first auxiliary xenotransplantation from a 10-gene-edited pig to a living human recipient - distinct from previous studies involving brain-dead recipients. The donor liver was engineered using a 10-gene editing platform, including the knockout of xenoantigen genes and the knock-in of seven human transgenes for immune and coagulation compatibility - pushing the boundaries of synthetic biology in clinical transplantation. The porcine graft exhibited metabolically active liver function, bile secretion, and coagulation correction, demonstrating not only survival but clinically meaningful function. Our work documents, for the first time, xenotransplantation-associated thrombotic microangiopathy in a living human recipient, with comprehensive immunological and histopathological analysis - critical knowledge for the field.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Zhang W, Xu Q, Xu K, et al. Genetically engineered pig-to-human liver xenotransplantation. J Hepatol. 2025. PMID: 41076089. doi:10.1016/j.jhep.2025.08.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。